27 April 2022

Director Dealing

Bioventix plc


(“Bioventix” or “the Company”)


Director Dealing


Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 26 April 2022 that on 25 April 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 3 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,500 pence per Ordinary Share (the “Purchase”). The shares were purchased under a dividend reinvestment plan (DRIP).


Following the Purchase, Bruce Hiscock has a beneficial interest in 424 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.


The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.



For further information please contact:


Bioventix plc

Peter Harrison


Chief Executive Officer

Tel: 01252 728 001
finnCap Ltd

Geoff Nash/Simon Hicks

Alice Lane


Corporate Finance


Tel: 020 7220 0500


This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”), and is disclosed in accordance with the company’s obligations under Article 17 of MAR.



Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them



1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Bruce Hiscock
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bioventix Plc
b) LEI 213800225MHX7LZQY108
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary Shares of 5 pence each
Identification code GB00B4QVDF07
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) 3 Ordinary Shares

3,500 pence

d) Aggregated information:


·     Aggregated volume


·     Price

Purchase of 3 Ordinary Shares at 3,500 pence each
e) Date of the transaction 25 April 2022
f) Place of the transaction London Stock Exchange, AIM Market (XLON)